2-(1-金刚烷基)吡咯烷盐酸盐 | 180258-96-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-(1-金刚烷基)吡咯烷盐酸盐
• 英文名称: 2-adamantan-1-yl-pyrrolidine
• 英文别名: 2-(1-Adamantyl)pyrrolidine
• CAS: 180258-96-2
• 化学式: C₁₄H₂₃N
• 分子量: 205.343
• InChiKey: YVRRAISBZUMEJB-UHFFFAOYSA-N

物化性质

• 沸点：
  289.8±8.0 °C(Predicted)
• 密度：
  1.066±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(1-金刚烷基)吡咯烷盐酸盐 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 50.0h， 生成 1-ethyl-2-(1-tricyclo[3.3.1.1^3,7]decyl)pyrrolidine
  参考文献：
  名称：

  Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2

  摘要：

  The synthesis of some new aminoadamantane derivatives is described. The new compounds were evaluated against a wide range of viruses [influenza A H1N1, influenza A H2N2, influenza A H3N2, influenza B, parainfluenza 3, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient (TK-) HSV-1, vaccinia, vesicular stomatitis, polio 1, Coxsackie B4, Sindbis, Semliki forest, Reo 1, varicella-zoster virus (VZV), TK- VZV, human cytomegalo-virus (HCMV),,and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)]. Some of them proved markedly active against the influenza A H2N2 (compounds 4a,b, 5a, 6a, and 7a), H3N2 (compounds 5a, 6a, and 7a), and H1N1 (compounds 4b,c and 6d). Since compounds 5a, 6a, and 7a, amantadine, and rimantadine showed the same comparative pattern of potency against influenza strains H2N2, H3N2, and B, it may postulated that they act according to a similar mechanism, with regard to their ''amine'' effect, on the M2 ion channel of influenza A (H1N1, H2N2, or H3N2). In general, no significant activity was noted with any of the new compounds against any of the other viruses tested, making their activity against influenza virus more specific and striking. Borderline activity was noted with some of the compounds (4b,c, 5a-c, and 8a) against HIV-1.

  DOI：

  10.1021/jm950891z
• 作为产物：
  描述：

  1-(金刚烷-1-羰基)吡咯烷-2-酮 在 sodium tetrahydroborate 、 溶剂黄146 、 calcium oxide 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 2-(1-金刚烷基)吡咯烷盐酸盐
  参考文献：
  名称：

  Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2

  摘要：

  The synthesis of some new aminoadamantane derivatives is described. The new compounds were evaluated against a wide range of viruses [influenza A H1N1, influenza A H2N2, influenza A H3N2, influenza B, parainfluenza 3, herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2), thymidine kinase-deficient (TK-) HSV-1, vaccinia, vesicular stomatitis, polio 1, Coxsackie B4, Sindbis, Semliki forest, Reo 1, varicella-zoster virus (VZV), TK- VZV, human cytomegalo-virus (HCMV),,and human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)]. Some of them proved markedly active against the influenza A H2N2 (compounds 4a,b, 5a, 6a, and 7a), H3N2 (compounds 5a, 6a, and 7a), and H1N1 (compounds 4b,c and 6d). Since compounds 5a, 6a, and 7a, amantadine, and rimantadine showed the same comparative pattern of potency against influenza strains H2N2, H3N2, and B, it may postulated that they act according to a similar mechanism, with regard to their ''amine'' effect, on the M2 ion channel of influenza A (H1N1, H2N2, or H3N2). In general, no significant activity was noted with any of the new compounds against any of the other viruses tested, making their activity against influenza virus more specific and striking. Borderline activity was noted with some of the compounds (4b,c, 5a-c, and 8a) against HIV-1.

  DOI：

  10.1021/jm950891z

文献信息

• APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20130096121A1

  公开（公告）日：2013-04-18

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bc1-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bc1-xL protein.

  揭示了抑制抗凋亡Bc1-xL蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bc1-xL蛋白的疾病的方法。
• Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
  申请人：AbbVie Inc.

  公开号：US08940737B2

  公开（公告）日：2015-01-27

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

  本发明涉及抑制抗凋亡Bcl-xL蛋白活性的化合物，包含该化合物的组合物以及用于治疗表达抗凋亡Bcl-xL蛋白的疾病的方法。
• APOPTOSIS-INDUCED AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：AbbVie Inc.

  公开号：US20160206611A1

  公开（公告）日：2016-07-21

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.

  本发明涉及一种抑制抗凋亡Bcl-xL蛋白活性的化合物，含有该化合物的组合物以及治疗表达抗凋亡Bcl-xL蛋白的疾病的方法。
• ANTIVIRAL COMPOUNDS
  申请人：BRIGHAM YOUNG UNIVERSITY

  公开号：US20150368196A1

  公开（公告）日：2015-12-24

  Compounds useful for treating and preventing viral infections including influenza are disclosed. Methods of treating or preventing viral infections, including influenza A infections are disclosed. Specifically, aminoadamantane derivatives that are structurally analogous to amantadine, including spirocyclic compounds, are provided for the treatment of amantadine-insensitive influenza infection in a subject.

  本文披露了用于治疗和预防包括流感在内的病毒感染的化合物。本文还披露了治疗或预防病毒感染，包括甲型流感感染的方法。具体而言，提供了与金刚烷胺结构类似的氨基金刚烷衍生物，包括螺环化合物，用于治疗对金刚烷胺不敏感的流感感染。
• Compositions and kits for treating influenza
  申请人：Adamas Pharmaceuticals, Inc.

  公开号：EP2450040A2

  公开（公告）日：2012-05-09

  Compositions, kits and methods are provided for the treatment or prophylaxis of influenza

  提供了用于治疗或预防流感的组合物、试剂盒和方法